Julie E Oomens, Sarah A Biber, Marilyn Albert, Michael L Alosco, Konstantinos Arfanakis, Tammie L S Benzinger, James B Brewer, Jeffrey M Burns, Erin Chin, Nathaniel A Chin, Lindsay R Clark, Ann D Cohen, Jeffrey L Dage, John A Detre, Bradford C Dickerson, Frank P DiFilippo, Michael C Donohue, Christopher H van Dyck, Audrey P Fan, Thomas J Grabowski, Mohamad Habes, Theresa M Harrison, Trey Hedden, Timothy J Hohman, William J Jagust, Angela L Jefferson, Gregory A Jicha, Steven R Kecskemeti, Kejal Kantarci, Dirk C Keene, Janice E Knoefel, Walter A Kukull, Weili Lin, Patrick Lao, Rebecca J Lepping, Swati R Levendovszky, Arjun V Masurkar, Jonathan E McConathy, Monica Rivera-Mindt, Darby J Morhardt, Douglas C Noll, Ozioma C Okonkwo, Todd B Parrish, Gil D Rabinovici, Annalise Rahman-Filipiak, Eric M Reiman, Shannon L Risacher, Howie Rosen, Marc D Rudolph, Lon S Schneider, Lisa C Silbert, Allen W Song, Craig E L Stark, Russel H Swerdlow, Paul M Thompson, David Vaillancourt, Victor L Villemagne, David A Wolk, Deqiang Qiu, Tatiana M Foroud, Sterling C Johnson, Elizabeth C Mormino
INTRODUCTION: The Consortium for Clarity in Alzheimer''s disease related dementias (ADRD) Research Through Imaging (CLARiTI) is a study that aims to collect standardized imaging and plasma biomarkers on 2000 Clinical Core participants enrolled across all Alzheimer''s Disease Research Centers (ADRC) sites. We sought to summarize the known heterogeneity across centers regarding scientific focus and initial enrollment plans for CLARiTI.'
